144 related articles for article (PubMed ID: 10936783)
1. Moc-31, fibronectin and CEA in the differential diagnosis of malignant effusions: an immunocytochemical study.
Athanassiadou P; Gonidi M; Liossi A; Petrakakou E; Nakopoulou L; Zerva C; Athanassiades P
Pathol Oncol Res; 2000; 6(2):100-3. PubMed ID: 10936783
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemical differentiation of reactive mesothelial cells and adenocarcinoma cells in serous effusions with the use of carcinoembryonic antigen and fibronectin.
Athanassiadou P; Athanassiades P; Lazaris D; Kyrkou K; Petrakakou E; Aravantinos D
Acta Cytol; 1994; 38(5):718-22. PubMed ID: 8091904
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies in the cytodiagnosis of serous effusions.
al-Nafussi A; Carder PJ
Cytopathology; 1990; 1(2):119-28. PubMed ID: 1714782
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotyping of mesothelial cells and carcinoma cells with monoclonal antibodies to cytokeratins, vimentin, CEA and EMA improves the cytodiagnosis of serous effusions.
Daste G; Serre G; Mauduyt MA; Vincent C; Caveriviere P; Soleilhavoup JP
Cytopathology; 1991; 2(1):19-28. PubMed ID: 1715202
[TBL] [Abstract][Full Text] [Related]
5. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
[TBL] [Abstract][Full Text] [Related]
6. Utility of fibronectin in immuocytochemial differentiation of reactive mesothelial cells from metastatic malignant cells in serous effusions.
Agarwal C; Jain M
Indian J Pathol Microbiol; 2009; 52(1):25-8. PubMed ID: 19136774
[TBL] [Abstract][Full Text] [Related]
7. The cytologic application of carcinoembryonic antigen for the discrimination of malignant from benign serous effusions.
Kyrkou KA; Iatridis SG; Athanassiadou PP; Athanassiadis PP; Mandragos CE
Cancer Detect Prev; 1985; 8(1-2):247-54. PubMed ID: 4064045
[TBL] [Abstract][Full Text] [Related]
8. Refined Diagnosis of Pleural Effusions by Immunocytochemistry of Cell Blocks.
Koyi H; Wilander E
Anticancer Res; 2023 Feb; 43(2):669-673. PubMed ID: 36697096
[TBL] [Abstract][Full Text] [Related]
9. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology.
Ko EC; Jhala NC; Shultz JJ; Chhieng DC
Am J Clin Pathol; 2001 Nov; 116(5):709-15. PubMed ID: 11710688
[TBL] [Abstract][Full Text] [Related]
10. Characterizing subpopulations of neoplastic cells in serous effusions. The role of immunocytochemistry.
Queiroz C; Barral-Netto M; Bacchi CE
Acta Cytol; 2001; 45(1):18-22. PubMed ID: 11213499
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
Hyun TS; Barnes M; Tabatabai ZL
Acta Cytol; 2012; 56(5):527-32. PubMed ID: 23075894
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical panel for distinguishing between carcinoma and reactive mesothelial cells in serious effusions.
Lee JS; Nam JH; Lee MC; Park CS; Juhng SW
Acta Cytol; 1996; 40(4):631-6. PubMed ID: 8693877
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions.
Hafez NH; Tahoun NS
J Egypt Natl Canc Inst; 2011 Dec; 23(4):155-62. PubMed ID: 22776843
[TBL] [Abstract][Full Text] [Related]
14. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
Klech H; Rona G; Hutter C; Bayer PM; Kummer F
Wien Klin Wochenschr; 1986 Sep; 98(17):564-73. PubMed ID: 3020811
[TBL] [Abstract][Full Text] [Related]
15. [The value of B7-H4 and carcinoembryonic antigen in diagnosing the benign and malignant pleural effusion].
Wei F; Wei Y; Li LF; Li GL; Wang GJ
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):524-527. PubMed ID: 28728299
[No Abstract] [Full Text] [Related]
16. Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma.
Shijubo N; Honda Y; Fujishima T; Takahashi H; Kodama T; Kuroki Y; Akino T; Abe S
Eur Respir J; 1995 Mar; 8(3):403-6. PubMed ID: 7789485
[TBL] [Abstract][Full Text] [Related]
17. Immunocytochemical profile of benign and carcinomatous effusions. A practical approach to difficult diagnosis.
Esteban JM; Yokota S; Husain S; Battifora H
Am J Clin Pathol; 1990 Dec; 94(6):698-705. PubMed ID: 1700877
[TBL] [Abstract][Full Text] [Related]
18. Tumor markers in the diagnosis of malignant serous effusions.
Cascinu S; Del Ferro E; Barbanti I; Ligi M; Fedeli A; Catalano G
Am J Clin Oncol; 1997 Jun; 20(3):247-50. PubMed ID: 9167746
[TBL] [Abstract][Full Text] [Related]
19. P53-immunoreactive cells in benign and malignant effusions: diagnostic value using a panel of monoclonal antibodies and comparison with CEA-staining.
Stoetzer OJ; Munker R; Darsow M; Wilmanns W
Oncol Rep; 1999; 6(2):455-8. PubMed ID: 10023021
[TBL] [Abstract][Full Text] [Related]
20. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I
Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
